💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib 20170927 💊Bristol-Myers Squibb Friday September 29th, 2017By Tokio X'press FDA, JPN ONO
👾Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan News Release 👾Opdivo® (Nivolumab) I Thursday September 21st, 2017By Tokio X'press JPN, TAI, Pharmaceutical ONO
Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea 20170919 Opdivo® (Nivolumab) Intravenou Tuesday September 19th, 2017By Tokio X'press JPN, Pharmaceutical ONO
ono、Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma ono、Opdivo Plus Yervoy Combina Wednesday September 13th, 2017By Tokio X'press JPN, Pharmaceutical ONO
Two important clinical trials of Ono Pharmaceuticals, Opivo® (generic name: niborumab) demonstrate the benefits of three-year survival in patients 20170911 Two important clinical trials Tuesday September 12th, 2017By Tokio X'press Cancer, JPN ONO
